Cargando…

Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1

AIMS: The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endothelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasminogen activator inhibitor-1 (PAI-1). We hypothesized that such pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouquet, Frédéric, Cuilleret, François, Susen, Sophie, Sautière, Karine, Marboeuf, Philippe, Ennezat, Pierre Vladimir, McFadden, Eugène, Pigny, Pascal, Richard, Florence, Hennache, Bernadette, Vantyghem, Marie Christine, Bertrand, Michel, Dallongeville, Jean, Jude, Brigitte, Van Belle, Eric
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663725/
https://www.ncbi.nlm.nih.gov/pubmed/19164335
http://dx.doi.org/10.1093/eurheartj/ehn569
_version_ 1782165919268601856
author Mouquet, Frédéric
Cuilleret, François
Susen, Sophie
Sautière, Karine
Marboeuf, Philippe
Ennezat, Pierre Vladimir
McFadden, Eugène
Pigny, Pascal
Richard, Florence
Hennache, Bernadette
Vantyghem, Marie Christine
Bertrand, Michel
Dallongeville, Jean
Jude, Brigitte
Van Belle, Eric
author_facet Mouquet, Frédéric
Cuilleret, François
Susen, Sophie
Sautière, Karine
Marboeuf, Philippe
Ennezat, Pierre Vladimir
McFadden, Eugène
Pigny, Pascal
Richard, Florence
Hennache, Bernadette
Vantyghem, Marie Christine
Bertrand, Michel
Dallongeville, Jean
Jude, Brigitte
Van Belle, Eric
author_sort Mouquet, Frédéric
collection PubMed
description AIMS: The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endothelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasminogen activator inhibitor-1 (PAI-1). We hypothesized that such patients, in the event of a coronary occlusion, might exhibit a less developed collateral circulation. METHODS AND RESULTS: Three hundred and eighty-seven consecutive patients with at least one coronary occlusion of a major coronary vessel at diagnostic angiography were prospectively enrolled. Collateral development was graded with validated angiographic methods. The MS was defined according to the ATP-III definition. Fasting glucose, adiponectin, insulin concentrations, and PAI-1 were measured at the time of angiography. MS was associated with less developed collateral vessels (P = 0.005). In multivariable analysis adjusting for potential confounding factors including the duration of coronary occlusion (P = 0.0001), fasting glycaemia (P = 0.0007), low adiponectin concentration (P = 0.01), insulin-resistance (HOMA-IR; P = 0.01), high circulating PAI-1 concentration (P = 0.01), and hypertension (P = 0.008) were independently associated with poor coronary collateral vessel development. CONCLUSION: This study shows that in patients with coronary occlusion, collateral circulation is impaired in patients with the MS. This association is partly related to fasting glycaemia and to key parameters linked to insulin resistance.
format Text
id pubmed-2663725
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-26637252009-04-02 Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 Mouquet, Frédéric Cuilleret, François Susen, Sophie Sautière, Karine Marboeuf, Philippe Ennezat, Pierre Vladimir McFadden, Eugène Pigny, Pascal Richard, Florence Hennache, Bernadette Vantyghem, Marie Christine Bertrand, Michel Dallongeville, Jean Jude, Brigitte Van Belle, Eric Eur Heart J Clinical Research AIMS: The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endothelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasminogen activator inhibitor-1 (PAI-1). We hypothesized that such patients, in the event of a coronary occlusion, might exhibit a less developed collateral circulation. METHODS AND RESULTS: Three hundred and eighty-seven consecutive patients with at least one coronary occlusion of a major coronary vessel at diagnostic angiography were prospectively enrolled. Collateral development was graded with validated angiographic methods. The MS was defined according to the ATP-III definition. Fasting glucose, adiponectin, insulin concentrations, and PAI-1 were measured at the time of angiography. MS was associated with less developed collateral vessels (P = 0.005). In multivariable analysis adjusting for potential confounding factors including the duration of coronary occlusion (P = 0.0001), fasting glycaemia (P = 0.0007), low adiponectin concentration (P = 0.01), insulin-resistance (HOMA-IR; P = 0.01), high circulating PAI-1 concentration (P = 0.01), and hypertension (P = 0.008) were independently associated with poor coronary collateral vessel development. CONCLUSION: This study shows that in patients with coronary occlusion, collateral circulation is impaired in patients with the MS. This association is partly related to fasting glycaemia and to key parameters linked to insulin resistance. Oxford University Press 2009-04 2009-01-22 /pmc/articles/PMC2663725/ /pubmed/19164335 http://dx.doi.org/10.1093/eurheartj/ehn569 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org
spellingShingle Clinical Research
Mouquet, Frédéric
Cuilleret, François
Susen, Sophie
Sautière, Karine
Marboeuf, Philippe
Ennezat, Pierre Vladimir
McFadden, Eugène
Pigny, Pascal
Richard, Florence
Hennache, Bernadette
Vantyghem, Marie Christine
Bertrand, Michel
Dallongeville, Jean
Jude, Brigitte
Van Belle, Eric
Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
title Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
title_full Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
title_fullStr Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
title_full_unstemmed Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
title_short Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
title_sort metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663725/
https://www.ncbi.nlm.nih.gov/pubmed/19164335
http://dx.doi.org/10.1093/eurheartj/ehn569
work_keys_str_mv AT mouquetfrederic metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT cuilleretfrancois metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT susensophie metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT sautierekarine metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT marboeufphilippe metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT ennezatpierrevladimir metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT mcfaddeneugene metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT pignypascal metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT richardflorence metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT hennachebernadette metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT vantyghemmariechristine metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT bertrandmichel metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT dallongevillejean metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT judebrigitte metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1
AT vanbelleeric metabolicsyndromeandcollateralvesselformationinpatientswithdocumentedoccludedcoronaryarteriesassociationwithhyperglycaemiainsulinresistanceadiponectinandplasminogenactivatorinhibitor1